Your session is about to expire
← Back to Search
MBX 2109 (Part A) for Healthy Subjects
Study Summary
This trial is evaluating the safety and tolerability of a new drug called MBX 2109 given as a shot under the skin. The study will also look at how well the drug is absorbed and how it affects the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Has MBX 2109 (Part A) obtained regulatory approval from the FDA?
"Due to limited data supporting both safety and efficacy, MBX 2109 (Part A) was ranked a 1 on our team's scale of risk."
How many participants are currently included in this investigation?
"Affirmative. According to the details on clinicaltrials.gov, this research project was initially posted in November 2021 and has since been updated in October 2022. 80 participants are required from two distinct hospitals for the trial's completion."
For what kind of participant is this experiment best suited?
"This medical trial seeks 80 adults aged 21-60 with healthy subject status. The other requirements include a BMI between 20 and 32, no clinically relevant findings from physical exams or lab tests, as well as being of non-childbearing potential."
Is there an age limit to be eligible for engaging in this research?
"To be eligible for this research, applicants must fall between 21 to 60 years old. There are 50 trials available for minors and 373 studies that focus on individuals over 65."
Are there any current vacancies available in this trial?
"Affirmative. The details shared on clinicaltrials.gov denote that recruitment for this research experiment is ongoing. This project, which was first posted in November 10th 2021, requires 80 volunteers from 2 locations to take part."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Average response time
- < 1 Day
Typically responds via
Most responsive sites:
- Labcorp Drug Development: Clinical Research Unit: < 24 hours
Share this study with friends
Copy Link
Messenger